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Long-term safety of ﬁlgrastim (rhG-CSF) administration
This journal recently included an article by Bennett et al
(2006) reporting ﬁve cases of haematological malignancy
occurring in normal individuals following exposure to
haematopoietic growth factors. Three cases described lym-
phoid malignancies (non-Hodgkin lymphoma and chronic
lymphocytic leukaemia) occurring months to years after
receipt of an investigational agent (pegylated, recombinant
megakaryocyte growth and development factor). The two
additional cases, however, were identiﬁed among 200 individ-
uals who had received ﬁlgrastim (recombinant human
granulocyte colony-stimulating factor; rhG-CSF, Neupogen )
as a mobilising agent for collection of peripheral blood stem
cells (PBSC) for allogeneic transplantation. The transplant
recipients for these latter two donors were their siblings, each
with acute myelogenous leukaemia (AML). The donors
themselves also developed AML 4–5 years following ﬁlgrastim
exposure.
It is known that siblings of persons with leukaemia have a 2–
5-fold increased annual incidence of leukaemia (Pottern et al,
1991; Shpilberg et al, 1994; Rauscher et al, 2002). In some
families, multi-generational occurrence of leukaemia, in the
absence of any known syndrome, e.g. Fanconi anaemia,
suggests direct inheritance of susceptibility genes (Segel &
Lichtman, 2004). Given these patterns, the contribution of
ﬁlgrastim exposure to the development of acute leukaemia
within families remains speculative.
Documenting the safety of ﬁlgrastim as a mobilising agent
for PBSC donation has long been a matter of importance for
the transplantation community, particularly in the context of
donations made by volunteer, unrelated adult donors. Since
1997, the US National Marrow Donor Program (NMDP) has
maintained an Investigational New Drug (IND) application
accepted by the Food and Drug Administration for manu-
facture of PBSC products from unrelated donors. Filgrastim is
administered for PBSC mobilisation at a total dose of c. 10 lg/
kg donor weight per day for 5 d. Under the IND protocols,
every donor provides informed consent for the research, which
includes agreement for perpetual annual follow-up. Among
4015 donors who have passed the ﬁrst anniversary of their
PBSC donation, we have accumulated 9785 years of follow-up
(range 1–9 years with 897 donors ‡4 years). Twenty cases of
cancer have been reported, occurring in various organ systems,
consistent with the age-adjusted US incidence of cancer in
adults and in support of the applicability of data obtained from
the NMDP follow-up system (Ries et al, 2006). There have
been no reports of leukaemia or lymphoma in this donor
cohort, which US statistics suggest should comprise 9% of all
malignancies in this age group.
National Marrow Donor Program donor consent forms
approved by the Institutional Review Board contain the
following information:
Normal individuals are at risk for developing cancer,
including leukaemia, lymphoma or other blood diseases
throughout their lifetime. It is unknown whether ﬁlgrastim
increases or decreases an individual’s risk of developing cancer.
The data being collected during follow-up will help establish if
there are any positive or negative long-term effects from
receiving ﬁlgrastim. Based on limited long-term data from
healthy people who have received ﬁlgrastim, no long-term risks
have been found so far.
The low occurrence of leukaemia and lymphoma in our
cohort of volunteer, unrelated PBSC donors should provide
reassurance to individuals who receive ﬁlgrastim for PBSC
mobilisation and should encourage their participation in
carefully designed programmes for follow-up monitoring. As
data from these and other studies mature, a more complete
assessment of overall donor safety will become available to all
interested parties.
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Long-term safety of ﬁlgrastim (rhG-CSF) administration:
application of haematopoietic growth factors in healthy
individuals
In light of the increasing frequency of peripheral blood stem
cell transplantation (PBSCT) requiring the application of
granulocyte colony-stimulating factor (G-CSF), the recent
article regarding haematological malignancies in previously
healthy individuals who received haematopoietic growth
factors by Bennett et al (2006) and the editorial comment
regarding the possible harmful effects of short course G-CSF in
normal donors, by Goldman et al (2006), address a highly
sensitive topic. Bennett et al (2006) reported on three out of
538 healthy volunteers who received pegylated recombinant
human megakaryocyte growth and development factor (PEG-
rHuMGDF) in the course of clinical studies and on two out of
200 stem cell donors who received G-CSF and subsequently
developed haematological malignancies 1–5 years after growth
factor administration. Long-term monitoring of healthy indi-
viduals who received human growth factors is essential and all
cases suspicious for long-term effects deserve the utmost
attention. However, in our view, the paper contains some
sensitive points:
First, the titles of the original article and of the editorial give
the impression that healthy individuals undergoing peripheral
stem cell mobilisation take a signiﬁcant risk. However, it
should be noted that PEG-rHuMGDF, which was administered
to cases 1–3, had already been withdrawn from clinical trials,
in 1998. This is mentioned shortly in the discussion (Bennett
et al, 2006), but should have been outlined clearly at the
beginning of the article. Moreover, the title of the article by
Bennett et al (2006) does not differentiate between the diverse
growth factors that were applied to the patients, whereas the
title of the editorial by Goldman et al (2006) deals exclusively
with G-CSF.
Secondly, cases 4 and 5 had received G-CSF when donating
stem cells for siblings with acute myeloid leukaemia (AML).
Familial clustering of haematological malignancies is well
known in AML (Smith et al, 2004) and in other entities, such
as lymphoma. This is in line with the positive family history for
AML in both the mother and brother of patient 4. These
aspects should have led to a more cautious interpretation of
the data. The importance of familial clustering is further
enhanced by occasional reports on the transmission of
haematological malignancies, such as AML, from related
donors to recipients by allogeneic haematopoietic stem cell
transplantation (HSCT) (Niederwieser et al, 1990).
Finally, the limited sample size of the study with only 200
individuals in the G-GSF cohort is a point of consideration.
When compared with some of the large retrospective analyses
that are cited by Bennett et al (2006), including up to 60 000
cases in the study of Pulsipher et al (2005) and more than
28 000 individuals in the study of Horowitz and Confer
(2005), their study contains rather few G-CSF treated cases
that may not be sufﬁcient for far-reaching conclusions.
Progress in allogeneic HSCT in recent years was only
possible following the establishment of allogeneic PBSCT and
depends to a very large extent on the motivation of the donors
and the support of the public. A renewed debate on the safety
of this procedure might easily destroy the results of the
tremendous efforts that were necessary to establish allogeneic
PBSCT in the routine setting. In light of the large number of
allogeneic PBSCT performed in the last 10 years without
apparent harm to donors, caution should be exerted with
respect to far-reaching conclusions based on the evaluation of
200 cases in a single study. Instead, analysis on possible
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